Gan & Lee Pharmaceuticals
Research Gan & Lee Pharmaceuticals (603087.SS) on Bullrun: market cap CNY 41.74B, P/E 36.0, dividend yield 1.4%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker603087.SS
- ExchangeSS
- CountryChina
- SectorHealthcare
- IndustryMedical Instruments & Supplies
- CurrencyCNY
- Market capCNY 41.74B
- P/E36.0
- Dividend yield1.4%
- Financial periodQ2 2026
- RevenueCNY 1.34B
- Net incomeCNY 417.29M
- Free cash flowCNY 42.11M
- Gross margin73.8%
Valuation Snapshot
latest market cap is CNY 41.74B; P/E is 36.0; dividend yield is 1.4%.
Peer valuation comparison
Latest P/E is 35.98x versus a Healthcare sector median of 21.69x (65.9% above).
Latest dividend yield is 1.44% versus a Healthcare sector median of 2.41% (40.2% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | CNY 41.74B | 36.0 | 1.4% | 1 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 1 CNY, yield 1.4%.
About Gan & Lee Pharmaceuticals
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the development, production, and commercialization of insulin analogs and medical devices in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro mix 75/25 injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, a mixed protamine human insulin injection.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Gan & Lee Pharmaceuticals's market cap?
Gan & Lee Pharmaceuticals's market capitalization is CNY 41.74B.
What is Gan & Lee Pharmaceuticals's P/E ratio?
Gan & Lee Pharmaceuticals's price-to-earnings (P/E) ratio is 36.0.
Does Gan & Lee Pharmaceuticals pay a dividend?
Gan & Lee Pharmaceuticals has a dividend yield of 1.4%.
What does Gan & Lee Pharmaceuticals do?
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the development, production, and commercialization of insulin analogs and medical devices in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro mix 75/25 injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, a mixed protamine human insulin injection. The company also offers GanleePen, an insulin injection device; and GanleeFine, an insulin pen needle.